NCT06232863 - A Study of BH009 in Head and Neck Squamous Cell Carcinoma and Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 18, 2023

Primary Completion Date

March 30, 2024

Study Completion Date

April 30, 2024

Conditions

Solid Tumor, Adult

Interventions

DRUG

BH009

Every 28 days constitutes a treatment cycle, and administration on day 1, day 8, day 15 of each cycle

Trial Locations (5)

RECRUITING

The First Affiliated Hospital of Bengbu Medical University, Bengbu

RECRUITING

The First Affiliated Hospital, Sun Yat-sen University, Guangzhou

RECRUITING

Hunan Cancer Hospital, Changsha

RECRUITING

Affiliated Zhongshan Hospital Of Dalian University, Dalian

RECRUITING

Obstetrics & Gynecology Hospital of Fudan University, Shanghai

All Listed Sponsors

lead

Zhuhai Beihai Biotech Co., Ltd

INDUSTRY